Comprehensive Clinical Guide: Aquablation Therapy for Benign Prostatic Hyperplasia (BPH)

1. Introduction & Overview

Benign Prostatic Hyperplasia (BPH) remains one of the most prevalent conditions affecting the aging male population. As the prostate gland enlarges, it exerts pressure on the urethra, leading to Lower Urinary Tract Symptoms (LUTS) that significantly impair quality of life. For decades, the gold standard for surgical intervention has been Transurethral Resection of the Prostate (TURP). However, TURP carries inherent risks, including sexual dysfunction, bleeding, and prolonged recovery.

Aquablation therapy represents a paradigm shift in urological surgery. It is a minimally invasive, robotically controlled, heat-free waterjet ablation procedure designed to remove prostate tissue with unparalleled precision. By combining real-time ultrasound imaging with autonomous robotic execution, Aquablation provides a standardized surgical outcome that is independent of surgeon fatigue or anatomical variability.

2. Technical Specifications & Mechanism of Action

The core technology behind Aquablation (marketed as the AquaBeam Robotic System) is the utilization of a high-velocity, saline-based waterjet. Unlike laser-based therapies (e.g., HoLEP or GreenLight) which rely on thermal energy to coagulate and vaporize tissue, Aquablation utilizes pure mechanical energy.

The Mechanism

1. Image-Guided Planning: The surgeon utilizes integrated transrectal ultrasound (TRUS) to map the prostate anatomy in real-time. This allows the surgeon to define the precise contour of the tissue to be removed while meticulously preserving the ejaculatory ducts and the bladder neck.
2. Robotic Execution: Once the plan is finalized, the robotic handpiece executes the resection autonomously. A high-pressure, non-thermal waterjet moves in a controlled sweep to ablate the obstructive tissue.
3. Non-Thermal Advantage: Because the procedure is heat-free, there is no risk of thermal injury to adjacent structures. This is a critical factor in preserving sexual function, as it minimizes the risk of collateral damage to the periprostatic nerves responsible for erectile function and ejaculation.

Comparison Table: Aquablation vs. Traditional Modalities

3. Clinical Indications & Patient Selection

Aquablation is indicated for men suffering from moderate to severe LUTS secondary to BPH. It is particularly advantageous for a specific subset of patients who have been historically difficult to treat.

Ideal Candidates

• Large Prostate Volumes: Patients with prostate volumes between 30mL and 80mL (and even exceeding 150mL, where other procedures might be technically challenging).
• Sexual Function Preservation: Men who prioritize the maintenance of erectile and ejaculatory function.
• Anatomical Complexity: Patients with complex prostate shapes or large median lobes that might complicate manual resection techniques.

Pre-Operative Preparation

1. Diagnostic Workup: Comprehensive International Prostate Symptom Score (IPSS) evaluation, uroflowmetry, and post-void residual (PVR) measurement.
2. Prostate Imaging: MRI or TRUS to rule out malignancy and assess the specific architecture of the hyperplasia.
3. Medication Management: Cessation of anticoagulants/antiplatelets per standard surgical protocols.
4. Infection Control: Prophylactic antibiotics are administered to prevent postoperative urinary tract infection (UTI).

4. The Procedure: A Step-by-Step Breakdown

The procedure is performed under general or spinal anesthesia in an operating room setting.

Step 1: Positioning and Setup

The patient is placed in the lithotomy position. The AquaBeam handpiece is inserted transurethrally. The ultrasound probe is placed rectally to provide a live, 3D visualization of the prostate.

Step 2: Mapping

The surgeon outlines the treatment area on the ultrasound screen. This "no-go" zone identification ensures that the sphincter and the ejaculatory ducts are shielded from the waterjet.

Step 3: Resection

The robotic system deploys the waterjet. The surgeon monitors the progress via the console. The waterjet cuts through the adenomatous tissue with high precision. Because it is a mechanical process, the tissue is removed systematically rather than being "shaved" or "burned" away.

Step 4: Hemostasis

Once the tissue is removed, the surgeon addresses bleeding vessels. While the waterjet itself does not coagulate, standard urological tools (electrocautery) are used to achieve final hemostasis. A Foley catheter is placed at the end of the procedure, typically for 24 hours.

5. Post-Operative Recovery Protocol

Recovery from Aquablation is generally faster and more comfortable than traditional invasive surgeries.

• Hospital Stay: Often an overnight stay or same-day discharge depending on the patient's baseline health.
• Catheterization: Patients usually go home with a catheter for 1–2 days.
• Activity Restrictions: Heavy lifting and strenuous exercise should be avoided for 2–4 weeks to prevent hematuria (blood in the urine).
• Follow-up: A follow-up appointment is scheduled at 4–6 weeks to assess IPSS scores and uroflowmetry, ensuring the patient has achieved the desired functional improvement.

6. Risks, Side Effects, and Contraindications

While Aquablation is highly safe, it is a surgical procedure and carries risks.

Potential Complications

• Bleeding: The most common complication. While usually managed with irrigation, some patients may require a blood transfusion in rare cases.
• Urinary Retention: Transient swelling may occur post-operatively, necessitating temporary re-catheterization.
• Dysuria: Mild burning during urination is common for the first few weeks as the tissue bed heals.
• Ejaculatory Changes: While Aquablation preserves ejaculatory function better than TURP, there remains a small risk of retrograde ejaculation.

Contraindications

• Active urinary tract infection.
• Presence of prostate cancer (unless otherwise cleared by oncology).
• Severe urethral stricture disease preventing the passage of the handpiece.
• Patients with significant bleeding diathesis (coagulopathy).

7. FAQ: Frequently Asked Questions

Q1: Is Aquablation covered by insurance?

Yes, in many jurisdictions, including the United States, Aquablation is covered by Medicare and most major private insurance providers for the treatment of BPH.

Q2: How long does the procedure take?

The actual resection time is usually less than 10 minutes, with the entire surgical process taking approximately 30 to 60 minutes.

Q3: Does Aquablation cause erectile dysfunction?

Because the procedure is non-thermal, there is virtually zero risk of heat-related damage to the nerves that control erections. Clinical trials have shown a very high rate of sexual function preservation.

Q4: Is this procedure only for very large prostates?

No. While it excels at handling large prostates, it is equally effective for small to medium-sized glands where precision is required to spare the ejaculatory ducts.

Q5: Will I need to stay in the hospital?

Many patients are discharged on the same day or the following morning.

Q6: How long until I see results?

Most patients notice a significant improvement in urine flow and a reduction in BPH symptoms within 2–4 weeks as the initial post-operative swelling subsides.

Q7: Can I have this procedure if I am on blood thinners?

Generally, you will need to pause blood thinners under the guidance of your cardiologist or primary care physician before the procedure to minimize bleeding risks.

Q8: How does it compare to UroLift?

UroLift is a mechanical implant procedure for smaller prostates. Aquablation is a more definitive surgical removal of tissue, suitable for a broader range of prostate sizes.

Q9: Will I need a catheter afterward?

Yes, a catheter is standard practice for 24–48 hours to allow the prostate bed to heal and ensure clear urine flow.

Q10: Does the procedure require general anesthesia?

It can be performed under spinal or general anesthesia. Your anesthesiologist will discuss the best option based on your medical history.

8. Summary of Outcomes

Clinical data from the WATER and WATER II trials demonstrate that Aquablation provides durable, long-term relief from BPH symptoms. Patients report significant improvements in IPSS scores, often seeing a 50% or greater reduction in symptom severity. Furthermore, the standardized, robotic nature of the procedure provides a consistent "clean" prostate channel, reducing the likelihood of secondary interventions compared to manual techniques.

Aquablation represents the future of BPH management: a perfect synthesis of robotic precision, non-thermal safety, and clinical efficacy. For the modern patient, it offers the most compelling balance between symptom relief and the preservation of quality of life.